What do systematic reviews say?

Epidermal growth factor vs best supportive care

The review found no eligible studies for this question.

• Therapeutic vaccines for advanced non‐small cell lung cancer 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Erlotinib vs control

Erlotinib leads to lower progression‐free survival compared with control (high certainty).

• First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes only
  HR 0.31 [0.25, 0.39]
  4 studies · 583 participants
  High

Gefitinib vs tri‐weekly paclitaxel plus carboplatin

Gefitinib leads to lower progression‐free survival compared with paclitaxel + carboplatin (high certainty).

• First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes only
  HR 0.39 [0.32, 0.48]
  2 studies · 485 participants
  High

Gefitinib vs pemetrexed + carboplatin with pemetrexed maintenance

Gefitinib probably leads to lower progression‐free survival compared with pemetrexed + carboplatin with pemetrexed maintenance (moderate certainty).

• First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes only
  HR 0.59 [0.46, 0.74]
  2 studies · 371 participants
  Moderate

Afatinib vs chemotherapy alone

Afatinib leads to lower progression‐free survival compared with chemotherapy (high certainty).

• First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes only
  HR 0.42 [0.34, 0.53]
  2 studies · 709 participants
  High

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Anti‐EGFR antibody plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  HR 0.9 [0.7, 1.16]
  4 studies · 658 participants
  Low

EGFR tyrosine kinase inhibitor (TKI) vs observation

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) changes progression‐free survival compared with observation alone (very low certainty).

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  HR 1.05 [0.9, 1.23]
  1 study · 835 participants
  Very low

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes progression‐free survival compared with chemotherapy alone (very low certainty).

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  HR 0.99 [0.69, 1.42]
  1 study · 129 participants
  Very low

Intervention not reported

The intervention leads to lower progression‐free survival (high certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 0.7 [0.6, 0.82]
  12 studies · 4402 participants
  High

Intervention not reported

The intervention probably leads to lower progression‐free survival (moderate certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 0.6 [0.48, 0.75]
  6 studies · 1237 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in progression‐free survival (moderate certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 1.13 [0.93, 1.36]
  6 studies · 2023 participants
  Moderate

Intervention not reported

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1483 participants
  High

Intervention not reported

The intervention showed no clear difference in progression‐free survival (high certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 1.02 [0.93, 1.12]
  4 studies · 2189 participants
  High

Intervention not reported

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 1651 participants
  Moderate

Intervention not reported

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 181 participants
  Low

Intervention not reported

It is very uncertain whether the intervention changes progression‐free survival (very low certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 1.04 [0.83, 1.29]
  6 studies · 1571 participants
  Very low

Intervention not reported

The intervention showed no clear difference in progression‐free survival (moderate certainty).

• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 1.03 [0.89, 1.2]
  8 studies · 2567 participants
  Moderate

Anti‐EGFR therapy vs placebo or usual care

Anti‐EGFR therapy showed no clear difference in progression‐free survival ‐ first‐line studies compared with placebo or standard of care (low certainty).

• Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
  HR 0.94 [0.81, 1.1]
  2 studies · 894 participants
  Low

Anti‐EGFR therapy vs placebo or usual care

Anti‐EGFR therapy may leads to lower progression‐free survival ‐ recurrent disease studies compared with placebo or standard of care (low certainty).

• Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
  HR 0.75 [0.58, 0.96]
  3 studies · 275 participants
  Low